改性壳聚糖医用膜对原发性翼状胬肉切除术后炎症与复发的影响:一项前瞻性随机临床研究
一项前瞻性随机单中心临床试验纳入54例(54眼)原发性翼状胬肉患者,比较单纯羊膜移植(AM组26眼)与羊膜移植联合结膜下植入改性壳聚糖医用膜(MCMM组28眼)的术后炎症与复发。随访3年,两组翼状胬肉复发率无显著差异(P=.903);MCMM组术后1个月泪液IL-8(P=.003)和TNF-α(P=.044)显著低于AM组,术后3至6个月IL-8亦显著降低(P=.016)。
要点
- MCMM组与AM组翼状胬肉复发率无显著差异(P=.903)。
- MCMM组术后1个月泪液IL-8和TNF-α水平显著低于AM组。
- MCMM组术后3至6个月泪液IL-8水平显著低于AM组。
核心结论
- MCMM有效降低泪液IL-8和TNF-α水平及术后眼表炎症,但与 traditional AMT 相比未显著影响长期复发率。
- 作者认为MCMM可能是减少翼状胬肉术后炎症、避免广泛剥离或抗代谢药物的有前景的选择。
研究设计与样本
- 前瞻性、随机、对照、单中心临床试验,纳入54例(54眼)原发性翼状胬肉患者,随机分为AM组26眼和MCMM组28眼,随访3年。
主要发现
- AM组角膜复发3例(11.5%)、结膜复发2例(7.7%);MCMM组角膜复发2例(7.1%)、结膜复发2例(7.1%);两组复发率无显著差异(P=.903)。
- 术后1个月,MCMM组泪液IL-8(P=.003)和TNF-α(P=.044)水平较AM组显著降低。
- 术后3至6个月,MCMM组泪液IL-8水平较AM组显著降低(P=.016)。
- 各组内复发与未复发患者比较,术后1个月TNF-α和IL-8均升高(AM组:TNF-α P=.039,IL-8 P=.001;MCMM组:TNF-α P=.003,IL-8 P=.047)。
- 两组年龄、眼压、视力和胬肉头长度无显著差异。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the role of intraoperative implantation modified chitosan medical membrane (MCMM) in postoperative inflammation and recurrence for primary pterygium excision with adjunctive amniotic membrane transplantation (AMT). DESIGN: Prospective, randomized, controlled, single-center clinical trial. METHODS: We included 54 patients (54 eyes) with primary pterygium scheduled for pterygium excision. They were randomly divided into two groups. The cryopreserved amniotic membrane (AM) group accepted pterygium excision with adjunctive AMT, and the MCMM group received AMT with adjunctive subconjunctival MCMM implantation during surgery. A follow-up of 3 years was conducted to observe pterygium recurrence. Primary outcomes included recurrence rate and tear cytokine levels after surgery. Secondarily, epidemiological data, visual acuity change, intraocular pressure (IOP), and ocular surface score were also collected. Data were analyzed using SPSS software version 26.0. The χ2 test and Student t test were used to compare qualitative and continuous quantitative variables, respectively. RESULTS: A total of 54 subjects with 54 eyes were included, 26 in the AM group and 28 in the MCMM group. Corneal recurrence of pterygium occurred in 3 cases (11.5%), whereas 2 cases (7.7%) showed conjunctival recurrence in the AM group. Two cases (7.1%) experienced corneal recurrence, and 2 cases (7.1%) had conjunctival recurrence in MCMM group. Nonetheless, there was no significant difference in the recurrence rate of pterygium between the AM and the MCMM group (P = .903). In the 1-month and 3 to 6-month groups postoperatively, the MCMM group showed a significant reduction in the levels of interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in the tear fluid compared to the AM group, respectively (IL-8: P = .003, TNF-α: P = .044, for 1 month; IL-8: P = .016 for 3 to 6 months, respectively), indicating that MCMM has a significant inhibitory effect on ocular surface inflammation after surgery. When comparing the patients with recurrent and non-recurrent conditions within each group after the surgery, both TNF-α and IL-8 showed an increase 1 month after the operation (AM group: TNF-α, P = .039, and IL-8, P = .001; MCMM group: TNF-α, P = .003, and IL-8, P = .047). There was no significant difference in age, IOP, visual acuity, and length of pterygium head between the two groups. CONCLUSION: MCMM effectively reduced IL-8 and TNF-α tear levels and postoperative ocular surface inflammation, although it did not significantly influence the long-term recurrence rates compared to traditional AMT. MCMM could be a promising option for reducing postoperative inflammation of pterygium and for avoiding extensive dissection or antimetabolites.
引用
- Hou S, Geng X, Li J, et al. The Effect of Modified Chitosan Medical Membrane on the Inflammation and Recurrence After Primary Pterygium Excision: A Prospective Randomized Clinical Study. Am J Ophthalmol. 2025. PMID: 41314274. doi:10.1016/j.ajo.2025.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。